SCHEMBL3003153

SCHEMBL3003153

C[Si](C)(C)n1cc(I)cn1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28355143 0.75 IDH1 (0.36)
SCHEMBL360179 0.69
SCHEMBL19155992 0.68 MPO (0.31) MPO
SCHEMBL31392816 0.67 MPO (0.32) MPO
SCHEMBL3686568 0.65
SCHEMBL31243248 0.65
SCHEMBL18776485 0.65
SCHEMBL28177518 0.63
SCHEMBL24044943 0.63
SCHEMBL5645868 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE HOLDINGS CORP (US) 2025-11-06 US disclosed
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine INCYTE HOLDINGS CORPORATION (US) 2025-03-11 US disclosed
EP-4501410-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS Incyte Holdings Corporation (US) 2025-02-05 EP disclosed
CN-119306753-A Methods for preparing JAK inhibitors and related intermediate compounds 因西特控股公司 2025-01-14 CN disclosed
EP-3272738-B1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE HOLDINGS CORP (US) 2024-11-13 EP disclosed
CN-108395433-B Methods for preparing JAK inhibitors and related intermediate compounds 因西特控股公司 2024-10-22 CN disclosed
CN-112105608-B Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one 因赛特公司 2023-07-14 CN disclosed
EP-4086245-A1 PROCESSES FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF A JAK INHIBITOR Incyte Corporation (US) 2022-11-09 EP disclosed
EP-3985008-A1 PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR Incyte Holdings Corporation (US) 2022-04-20 EP disclosed
EP-3985008-A1 PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR Incyte Holdings Corporation (US) 2022-04-20 EP disclosed
US-20130253191-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION (US) 2013-09-26 US disclosed
US-8410265-B2 Processes for preparing JAK inhibitors and related intermediate compounds INCYTE CORPORATION (US) 2013-04-02 US disclosed
US-8410265-B2 Processes for preparing JAK inhibitors and related intermediate compounds INCYTE CORPORATION (US) 2013-04-02 US disclosed
US-8410265-B2 Processes for preparing JAK inhibitors and related intermediate compounds INCYTE CORPORATION (US) 2013-04-02 US disclosed
CN-102348693-A Methods for preparing JAK inhibitors and related intermediate compounds INCYTE CORP 2012-02-08 CN disclosed
EP-2398774-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS Incyte Corporation (US) 2011-12-28 EP disclosed
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION 2010-07-29 US disclosed
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION 2010-07-29 US disclosed
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION 2010-07-29 US disclosed
WO-2010083283-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine DPYD, TYMS, TYMP MPO 3209/4885
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 MPO 978/4885
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 MPO 978/4885
US-20130253191-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 MPO 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.